Rentschler Biotechnologie GmbH has signed a contract with Maxygen Holdings Ltd., a wholly owned subsidiary of Maxygen, Inc., for the manufacture of a novel factor VIIa protein therapeutic. This follows a recent agreement between Maxygen and Roche to co-develop and commercialize the protein for multiple clinical indications. Rentschler will set up the GMP-process and manufacture the drug to supply the clinical studies. Additionally, Maxygen and Roche have an option to retain Rentschler as co...